Biogen Inc Cedear BIIB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- 2.88
- Price/Sales
- 0.65
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Mid Value
- Total Number of Employees
- 7,570
- Website
- https://www.biogen.com
Competitors
Valuation
Metric
|
BIIB
|
NVS
|
SNY
|
---|---|---|---|
Price/Earnings (Normalized) | 2.88 | 14.88 | 10.71 |
Price/Book Value | 0.22 | 5.28 | 1.60 |
Price/Sales | 0.65 | 4.27 | 2.42 |
Price/Cash Flow | 2.70 | 14.17 | 11.94 |
Price/Earnings
BIIB
NVS
SNY
Financial Strength
Metric
|
BIIB
|
NVS
|
SNY
|
---|---|---|---|
Quick Ratio | 0.92 | 0.61 | 0.83 |
Current Ratio | 2.00 | 0.90 | 1.27 |
Interest Coverage | 5.13 | 11.32 | 8.40 |
Quick Ratio
BIIB
NVS
SNY
Profitability
Metric
|
BIIB
|
NVS
|
SNY
|
---|---|---|---|
Return on Assets (Normalized) | 8.32% | 13.39% | — |
Return on Equity (Normalized) | 15.02% | 31.09% | — |
Return on Invested Capital (Normalized) | 10.29% | 19.67% | — |
Return on Assets
BIIB
NVS
SNY
Drug Manufacturers - General Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Hlgtsdpvt | Gvqz | $732.9 Bil | |
JNJ
| Johnson & Johnson | Qhtkrkk | Ylpgw | $372.2 Bil | |
MRK
| Merck & Co Inc | Nngvtlv | Nppz | $332.3 Bil | |
ABBV
| AbbVie Inc | Fcnnvpdmx | Jhc | $290.2 Bil | |
AZN
| AstraZeneca PLC ADR | Xrzcxhfj | Swgz | $237.9 Bil | |
RHHBY
| Roche Holding AG ADR | Vdjdtpzj | Yhpky | $211.1 Bil | |
NVS
| Novartis AG ADR | Zkxyqnp | Bsjl | $210.2 Bil | |
AMGN
| Amgen Inc | Pyhzmyhcnx | Hdtz | $167.6 Bil | |
PFE
| Pfizer Inc | Bbpjxbv | Rmzc | $162.3 Bil | |
SNY
| Sanofi SA ADR | Ygrrjcxcq | Lfpc | $121.1 Bil |